Cantor Fitzgerald Raises United Therapeutics (UTHR) Price Target to $625

Core Insights - United Therapeutics Corporation (NASDAQ: UTHR) is recognized as one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026 [1] Group 1: Price Target and Investment Catalysts - Cantor Fitzgerald raised its price target on United Therapeutics from $525 to $625, maintaining an Overweight rating on the stock [2] - The primary investment catalyst for the company is idiopathic pulmonary fibrosis, with significant upside expected if the TETON-1 clinical trial yields positive results [2] - Analysts predict that the stock's per-share value could exceed $600 in the coming months, enhancing the company's leadership in treating critical lung conditions [2] Group 2: Stock Repurchase Program - United Therapeutics authorized a new $2 billion stock repurchase program, initiating a $1.5 billion accelerated share repurchase (ASR) with Citibank [3] - The ASR includes both collared and uncollared structures, with an upfront payment made on March 11, followed by the delivery of approximately 50% to 70% of the anticipated shares [3] - The remaining $500 million of the repurchase program is available for discretionary buybacks over a one-year period [3] Group 3: Company Overview - Founded in 1996, United Therapeutics is a biotechnology company focused on rare lung diseases and is headquartered in Silver Spring, Maryland [4] - The company develops pharmaceuticals and technologies related to organ transplantation [4]